PSMD14 and plasma cell myeloma: The UPS is a central pathway that regulates intracellular protein degradation and has become a significant target for cancer treatment.[38] Currently, proteasome inhibitors such as bortezomib have achieved significant efficacy in the treatment of multiple myeloma.[39] For the past few years, the natural product thiolutin has garnered attention because of its anti‐inflammatory, antiangiogenic, and antitumor activities.[40] Notably, significant tumor inhibition was observed in a mouse model in which the PSMD14 inhibitor thiolutin was used or PSMD14 was knocked down.